26 August 2019
The CD37-mutated lymphoma B-cells show impaired CD37 cell surface localization, which has important implications for anti-CD37 immunotherapy.
Suraya Elfrink, together with Lotte de Winde and Michiel van den Brand, in Annemiek van Spriel's research group Immune cell signaling, theme Cancer development and immune defense, published a manuscript in Blood reporting that tetraspanin CD37 is frequently mutated in patients with diffuse large B cell lymphoma occurring at immune-privileged sites.
The CD37-mutated lymphoma B-cells show impaired CD37 cell surface localization, which has important implications for anti-CD37 immunotherapy.